Piramal Pharma Consumer Products Division’s Tri-Activ Disinfectant Spray For Multi-Surfaces is 99.9% Effective Against the Covid-19 Virus in 1 Minute

▴ Piramal Pharma Consumer Products Division’s Tri-Activ Disinfectant Spray For Multi-Surfaces is 99.9% Effective Against the Covid-19 Virus in 1 Minute
This spray has been tested and proven for efficacy as well as fast action on the Covid19 virus by an independent accredited US-based lab.

Piramal Pharma Limited’s Consumer Products Division today announced that its Tri-Activ Disinfectant Spray for multi-surfaces is “99.9% effective against the Covid-19 virus in 1 minute”. This spray has been tested and proven for efficacy as well as fast action on the Covid19 virus by an independent accredited US-based lab. The Tri-Activ Disinfectant Spray can be used to disinfect a variety of hard and soft surfaces including delivery parcels, non-leather car interiors and shoes, glass table tops, door handles and knobs, lift buttons, children’s toys and cycles, and non-satin clothes, sofas, curtains and mattresses. Its regular usage also keeps fungus and mould away from high touch surfaces. This spray is available in 3 pack sizes – 100ml (convenient to carry), 230ml (medium) and 500ml (large) at affordable prices. Nandini Piramal, Director, Piramal Pharma Limited said, “With the threat of Covid-19 and the uncertainty around it, the demand for sanitization and disinfectant products is on a significant rise as personal hygiene and environment sanitization is of paramount importance. Piramal’s Consumer Products Division launched the Tri-Active range of products with an aim to provide complete protection to its consumers by catering to their various personal and household needs. Our Tri-Activ Disinfectant Spray is tested and proven to be 99.9% effective against the corona virus in 1 minute. Committed to our purpose of Doing Well and Doing Good, we’re now enabling more consumers to make their world ‘Tri-Activ’ safe.” Piramal’s Consumer Products Division recently launched its disinfectant product portfolio under the brand name Tri-Activ in Q1 FY2021. The products under this portfolio offer customers a complete range of protection from virus, bacteria and other germs. In addition to having adopted a WHO approved hand sanitizer liquid, this range comprises a variety of products including disinfectant spray, hand sanitizer gel, multi-purpose disinfectant liquid, as well as a 6-layer protective face mask with an anti-virus coating. Adopting an e-commerce first strategy, the complete Tri-Activ range of products is available across all major sales channels including general trade, modern trade and leading e-commerce platforms. Tri-Activ sprays and sanitizers are available at 50,000+ outlets in 177 townsin India across chemist and non-chemist channels. Currently, ~3,000 Tri-Activ range products are sold daily over e-commerce, contributing to ~50% of the range’s total sales.

Tags : #LatestPharmaNewsOct27 #LatestPiramalNewsOct27 #DisinfectantsprayforCOVID19 #TriActivDisinfectantSpray

About the Author


Sana Farid Khan

“The best way to become acquainted with a subject is to write about it."
A confident counselor, a speaker, and an educator, ready to utilize my communication skills effectively in the world of healthcare by putting pen to paper to reach new heights of success.
You can write to me at [email protected]

Related Stories

Loading Please wait...
-Advertisements-


Trending Now

Covid technical Advisory panel advises Karnataka health dept to be prepared for 2nd wave of COVID-19 pandemicDecember 04, 2020
Telangana reports 631 fresh cases of COVID-19December 04, 2020
Odisha crosses milestone in conducting over 6 million tests for COVID-19December 04, 2020
New Phase 3 Data Show TAK-620 (maribavir), an Investigational Drug for the Treatment of Transplant Recipients with Refractory/Resistant Cytomegalovirus (CMV) Infections, Meets Primary EndpointDecember 04, 2020
Shape Therapeutics Unveils AAVid™ Capsid Discovery Platform and Identification of Novel Tissue-Specific AAV Variants, Solving a Fundamental Delivery Challenge in Gene TherapyDecember 04, 2020
ReAlta Life Sciences Announces EMA Orphan Drug Designation for RLS-0071 for the Treatment of Neonatal EncephalopathyDecember 04, 2020
I2O Therapeutics receives strategic investment from Colorcon VenturesDecember 04, 2020
Study shows personalized provider navigation using machine intelligence may reduce post-surgical hospitalizations and lower costsDecember 04, 2020
Zydus receives approval from DCGI to commence Phase III clinical trials with Pegylated Interferon alpha-2b in India December 04, 2020
PharmaEngine, Inc. collaborates with Sentinel Oncology for SOL-578, a Chk1 inhibitorDecember 04, 2020
Rhizen Pharmaceuticals Announces US FDA Acceptance of its IND ApplicationDecember 04, 2020
1450 new cases of COVID-19 reported in Madhya PradeshDecember 04, 2020
COVID-19 recovery rate in country improves to 94.20 pctDecember 04, 2020
Over 11,70,000 samples tested for COVID-19 across country in last 24 hoursDecember 04, 2020
Britain to cover COVID-19 vaccine side-effects under damages schemeDecember 04, 2020
India’s Active Caseload further dips to 4.35% of Total CasesDecember 04, 2020
COVID-19 recovery rate in Bihar improves to 97.12 pctDecember 04, 2020
Gujarat records 1540 new cases of COVID-19December 04, 2020
Catalyst Biosciences receives FDA Fast track designation for subcutaneous MarzAADecember 04, 2020
AbbVie and Frontier Medicines establish global partnership for research and developmentDecember 04, 2020